Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.

by Gabriel Tremblay, Heather J McElroy, Tracy Westley, Genevieve Meier, Derek Misurski, Matthew Guo
Published 2019-01-01